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Introduction 
 
Deliberate  self-harm  is  one  of  the  most common  problems  we  encounter  in  our 
community. Poisoning is one of the common methods of deliberate self-harm in the world. 
Poisoning by organophosphorus compound consumption is common among  developing 
countries such as India and Srilanka. 
Organophosphorus poisoning can occur by deliberate ingestion or accidental exposure to skin 
or by ingestion.  Morbidity and mortality associated with organophosphorus poisoning is due 
to development of intermediate syndrome which develops 3 days after the consumption. But 
currently there are no effective ways of predicting the development of intermediate syndrome 
in patients who present with organophosphorus poisoning. Predicting the most common 
complication of organophosphorus poisoning can help in managing the patient better with 
accurate triaging of patients to the ICU or to ward. 
Organophosphorus induced Encephalopathy has been described in patients with 
organophosphorus poisoning, both as an early as well as delayed manifestation. But the 
relationship between the central encephalopathic manifestations and peripheral 
neuromuscular manifestations have not been studied in detail. 
In our study we propose to develop a clinical scoring tool to predict the development of 
intermediate syndrome in patients who present with organophosphorus poisoning and 
describe the temporal profile of central and peripheral neurological manifestations of 
organophosphorus poisoning. 
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AIMS 
 
To describe and correlate the central (encephalopathic) and peripheral neuromuscular features 
(Type 1 and Type II [Intermediate syndrome]) and their temporal profile in acute 
organophosphorus poisoning. 
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OBJECTIVES 
 
1. To assess the utility of a clinical scoring system at admission to predict the development 
of Intermediate syndrome in patients with acute Organophosphorus poisoning. 
 
2. To describe and correlate the central (encephalopathic) and peripheral neuromuscular features 
(Type 1 and Type II [Intermediate syndrome]) and their temporal profile in acute 
Organophosphorus poisoning. 
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REVIEW OF LITERATURE 
Deliberate self-harm is one the common problems in community. Suicide by consumption of 
poison is a common practice especially in developing countries and more than half the 
suicides in the world occur in India and China(1).  
Pesticide poisoning due to organophosphorus compound consumption is a common method 
of suicide in southern India and Sri Lanka. In our institution Organophosphorus poisoning 
accounted for 12%  of all intensive care admission and 70 % all admissions with a case 
fatality rate of 22 %.(2). 
CHEMICAL COMPOSITION OF ORGANOPHOSPHORUS COMPOUND 
All organophosphorus compounds have a similar chemical composition. They contain a  
central phosphorous atom attached to either a sulphur or oxygen by a double bond. All 
organophosphorous compound contains either a methyl or ethyl group along with a leaving 
group which is specific to every organophosphorous compound(3). 
 
Figure 1 Chemical structure of OP compounds 
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MECHANISM OF ACTION OF ORGANOPHOSPHOROUS COMPOUND 
Organophosphorus compound act by inhibiting carboxy ester hydrolases like 
acetylcholinesterase (AChE) enzyme by binding to the active site of the enzyme(4). AChE 
acts by splitting acetylcholine in the neuromuscular junction.  
Acetyl cholinesterase is present in almost all living animals, vertebrates and invertebrates and 
is responsible for nervous conduction in organs and glands supplied by the parasympathetic 
arm of autonomic nervous system. Acetyl cholinersterase is complex molecule containing 
two main subsites, the esteratic and the anionic sites. Positively charged nitrogen atom of 
Acetyl choline enzyme and negatively charged anionic site of acetyl cholinesterase form the 
Enzyme-substrate(EA) complex. The EA complex then undergoes acetylation and de-
acetylaion at the serine hydroxyl group in the esteratic site which leads to the hydrolysis of 
the acetylcholine enzyme. The choline group which is formed is returned to the presynaptic 
neuron where acetyl choline is resynthesized form further action. One other type of acetyl 
cholinesterase is the plasma pseudocholinestrase which has high specificity for butrylcholine. 
The exact function of plasma pseudocholinestrase is still unknown but it is widely used for 
identifying acute organophosphorus poisoning. 
We have so far discussed the mechanism of action of acetyl cholinesterase. In the next 
section we will discuss how organophosphorus compounds act to cause the cholinergic and 
nicotinic side effects.  
The inhibition of Acetylcholinesterase takes place through a similar chemical reaction. The 
serine hydroxyl subsite combines with organophosphorous compound through acetylation. 
Unlike the easily reversible acetylation of the acetylcholinesterase enzyme , the 
phosphorylated compound maybe highly stable and sometimes be irreversible. 
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Mechanism of Activation 
Most of the organophosphorous compound contain the P==S moiety which is metabolically 
inactive. During activation, the P==S moiety is converted to P==O moiety, which are a more 
reactive and less stable group when compared to the former group. The chemical conversion 
is mediated by a unique enzyme the Mixed function oxidase (MFO). Classical example of 
this chemical reaction is conversion of Parathion(inactive) to Paroxoan (chemically active 
and  a strong anticholinesterase).(5) 
Mechanism of Degradation 
Organophosphorus compounds undergo hydrolytic (chemical or enzymatic hydrolysis) 
degradation to form metabolically inactive compounds. Enzymes which mediate the 
hydrolysis are called hydrolases or phosphotriester hydroloases. 
After degradation, elimination of the Organophosphorus compound is mainly through urine 
and faeces.  
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Figure 1 Mechanism of action of Organophosphorus compound 
(Picture taken from organophosphates pesticides and child health(6). 
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CLASSIFICATION BASED ON LETHALITY 
 
GHS (Global harmonised system) classification and WHO recommended classification are 
the most commonly used classification of organophosphorus compound based on their 
lethality. 
Although the GHS classification is a widely accepted classification system, we have adapted 
the WHO recommended classification (2009 update) in this study. 
The classification is done based the lethal dose (LD50) measures on rats both for oral as well 
as dermal exposure. Lethal dose (LD50) is amount of toxin (mg per kg of body weight) 
required for killing 50% of the population.  
 
Table 1 WHO classification of Pesticides(2009 update) 
 
(Table adapted from WHO recommended classification of pesticides by hazard and 
guidelines to classification)(7). 
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Some of the commonly used pesticides and their WHO class are as follows. 
Class Ia –       Methyl Parathion 
                       Phorate 
Class Ib -        Triazophos 
                       Dichlorvas 
                       Monocrotophos 
Class II -         Chlorpyriphos 
                        Phenthoate 
                       Quinalphos 
                       Dimethoate 
                       Profenophos 
Class III –       Acephate 
                        Malathion 
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CLASSIFICATION BASED ON TYPE OF COMPOUND 
 
Organophosphorus compounds contain an alkyl group which can be either an methyl/ethyl/s-
alkyl group. There are studies which have shown that poisoning with dimethyl compounds 
have a worse outcome when compared to poisoning with ethyl compounds.(8)(9) This may 
be attributed to the fact that dimethyl compounds have a shorter half life (half life of dimethyl 
– 3 hours, diethyl – 30hours) and a lower capacity for regeneration with oximes.(10).  
 
Table 2 Classification of OP based on alkyl group 
Dimethyl Diethyl S-alkyl 
Monocrotophos Phorate Profenofos 
Methylparathion Triazophos  
Dichlorvas Parathion  
Dimethoate Quinalphos  
Phenthoate Chlorpyriphos  
Malathion Ethion  
Acephate   
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CLINICAL MANIFESTATIONS 
Clinical manifestations of organophosphorus poisoning can be divided as 
1) Cholinergic manifestations 
 
2) Neurological manifestations 
 
CHOLINERGIC MANIFESTATIONS 
Cholinergic manifestations can be further divided based on the type of receptors 
involved.(11) 
1) Muscarinic symptoms – involving the muscarinic receptors 
 
2) Nicotinic symptoms – involving the nicotinic receptors 
 
3) Central symptoms – involving receptors in the central nervous  
 
system. 
 
 
Cholinergic symptoms are described in the following table. 
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MUSCARINIC 
 
NICOTINIC 
 
CENTRAL 
Respiratory 
Bronchorrhea/bronchospasm 
Rhinorrhea 
 
 Anxiety 
Restlessness 
Convulsion 
Cardiovascular 
Bradycardia 
Hypotension 
 
Cardiovascular 
Tachycardia 
Hypertension 
Insomnia 
Dysarthria 
Tremors 
Gastro-intestinal 
Increased salivation 
Nausea/vomiting 
Abdominal pain 
Diarrhoea 
Fecal incontinence 
 
Musculoskeletal 
Weakness 
Fasciculation 
Cramps 
Paralysis 
Coma 
Absent reflex 
Cardiovasucular collapse 
Respiratory suppression 
Genito-urinary 
Urinary incontinence 
  
Ocular 
Lacrimation 
Blurred vision(miosis) 
  
Table 3 Cholinergic manifestations of acute Op poisoning 
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NEUROLOGICAL SYMPTOMS 
 
Neurological manifestations of organophosphate poisoning have been described as early as in 
1974 by Wadia et.al.(12) 
Neurological paralysis as described by Wadia et.al was divided into the following categories. 
1) Type 1a paralysis – present at admission and seen in patient who present  
 
early after the organophosphorus consumption(less than 4 hours). 
 
Wadia et al described 11 patients with Type 1a paralysis. 
 
         Type 1b paralysis – Present at admission and seen in patients who present  
          late after organophosphorus consumption(later than 4 hours). 
          Type 1b paralysis was described in 10 patients in the same study. 
Type 1 paralysis chiefly included bilateral pyramidal tract signs which respond well to 
treatment with atropine. 
2) Type 2 paralysis – Paralysis which is not present at admission but which  
 
develops while on treatment with atropine. 
 
Wadia et al had described type 2 paralysis in 36 patients in their study out of whom 15 
patients had expired after requiring mechanical ventilation for different periods of time. They 
had also noticed that type 2 paralysis was not influenced by treatment with atropine and 
hence had concluded that type 2 paralysis was caused by nicotinic effects rather than 
muscarinic effects. 
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Other neurological manifestations described in this study were muscarinic effects such as 
miosis which almost universally present, impairment of consciousness was present in 10% of 
the patients, fasciculations were present in 27% of the patients, seizures were present in 1 % 
and toxic delirium(probably secondary to atropine treatment) was present in 50% of the 
patients. 
Senanyake et al described and coined the ‘intermediate syndrome’ while describing paralysis 
in 10 patients with organophosphorus poisoning.(13) 
Later studies done in our institution has shown that Type I and Type II paralysis may not be 
as distinct as described by Wadia et.al and the Type I and Type II paralysis maybe a 
continuum disorder that we refer to as the Type I-Type II continuum.(14) 
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DELAYED ORAGANOPHOSPHOROUS  INDUCED PERIPEHRAL 
NEUROPATHY 
 
Neurological manifestation of organophosphorous poisoning can be divided based on 
timeline of the symptoms. 
Neurological manifestations which arise 1 – 4 weeks after acute organophosphorous 
poisoning has been described which are commonly referred to as Organophosphorous 
induced peripheral neuropathy (OPIDN).(15) 
The manifestations are markedly different from the early neurological manifestations. These 
patients typically have peripheral nerve involvement and present with predominant motor 
neuropathy. They present with distal neuromuscular weakness involving lower limbs. Severe 
cases can have upper limb involvement also along with bilateral foot drop and wrist drop 
with depressed reflexes. Generally recovery is complete especially in the young and may take 
upto 3-6 months. Electrophysiological studies show decreased compound muscle action 
potential, increased distal latencies and nerve muscle biopsy have shown axonal degeneration 
and secondary demyelination.  
Pathophysiology is still not fully understood although, Neuropathy target esterase (NTE) 
have implicated in the initiation of OPIDN.  
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DELAYED ORGANOPHOSPHOROUS ENCEPHALOPATHY (DOPE) 
 
Encephalopathy has been described in patients with organophosphorus poisoning. 
Encephalopathy can manifest early in the course of the disease or can be a delayed 
manifestation. Delayed encephalopathy was described by Peter et.al in his study of 35 
patients with acute organophosphate poisoning.(16) 3 patients had developed deep coma 
(GCS-2T) lasting for 4.3+/-2.1 days and 3 patients had developed low sensorium (GCS 3T-
7T) lasting for 4.7+/-2.1 days. All 6 patients after variable duration of low sensorium (8+/-2 
days) improved to normal sensorium and were discharged and alive. 
The study had also noticed that all the 6 patients who had encephalopathy had intermediate 
syndrome.  
The definition of delayed encephalopathy in this study was development of low sensorium 
after initial 72 hours of normal sensorium. The study had excluded patients who present with 
altered sensorium. But early encephalopathy has been described by Wadia et al in his study 
where 50% of the patients were reported to have toxic delirium. Hence it is clear that 
encephalopathic manifestations can an early or a delayed manifestation. 
Early encephalopathy is predominantly attributed to central manifestations of the cholinergic 
crisis itself and respond to treatment with atropine. The pathophysiology behind delayed 
manifestations of encephalopathy is not fully understood. Probable mechanisms of delayed 
encephalopathy have been postulated. Administration of organophosphate induces excitatory 
changes in animal models which are suppressed by centrally acting anti-cholinergics such as 
atropine and CNS depressants such as diazepam.(17) Presence of persistently low 
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pseudocholinestrase at the onset of delayed encephalopathy suggests that acetylcholinesterase 
inhibition in the CNS may underlie the encephalopathy. Presence of intermediate syndrome 
in all patients who exhibited encephalopathy suggests a common mechanism which maybe 
involved in both the diseases.  
But nevertheless, the study demonstrated bihemispheric slow wave disturbances in these 
patients suggestive of CNS depression rather than overstimulation as cause of the 
encephalopathy. 
In our study, we have looked at the temporal profile of development of neuroparalysis and 
encephalopathy and the possibility that the central and peripheral manifestations of 
organophosphate poisoning as a continuum disorder rather than two separate disease 
processes. 
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ELECTROPHYSIOLOGICAL STUDIES 
Electrophysiological abnormalities have been described in acute organophosphorus poisoning 
in 1987 by Wadia et.al. In this study, they had examined 66 patients who had presented with 
acute organophosphorous poisoning with and without weakness. Wadia et. al. had shown that 
the nerve conduction study was normal or mildly slowed, the compound muscle action 
potential showed reduction, repetitive nerve conduction studies showed possibility of 
neuromuscular junction abnormality and single muscle stimulation showed repetitive 
response.(18) 
Serial neuro-electrophysilogical studies were done by Avasthi and was correlated with 
clinical weakness, serum cholinesterase and atropine dose in 19 patients with intermediate 
syndrome. He had shown that 30 Hertz repetitive nerve stimulation correlated well with 
weakness seen clinically (sensitivity = 61.72%; specificity = 81.54%; PPV= 73.91%; NPV = 
71.62%) and concluded that it could be a useful marker for identifying intermediate 
syndrome.(19) 
The largest electrophysiological study was done by Jayawardene et al where they had 
performed repetitive nerve stimulation in the right and left median and ulnar nerve at low and 
high frequencies.  
Important finding from this study were:- 
a) They had shown patients preceding the weakness had a decrement- 
 
increment pattern. 
 
b) Initially when developing weakness the patients showed decrement- 
 
increment pattern only in high and intermediate frequencies and as the  
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weakness progressed the decrement-increment pattern was seen in low  
 
frequencies as well. 
 
c) Severe decrement pattern and subsequent CMAPS not returning to the  
 
first CMAPs also was noted in patients with severe weakness and  
 
respiratory failure. 
 
In the same study, Jayawardene had noted that electrophysiological changes were present in 
patients who did not have clinical weakness and preceding the development of intermediate 
syndrome. These observations lead her to propose the idea that the Type I and Type II 
weakness were not separate disease entity and they were probably a spectrum disorder. 
Patients with electrophysiological changes and with either no clinical weakness or mild to 
moderate weakness were termed ‘forme fruste’ intermediate syndrome. 
A proposed electrophysiological criteria for diagnoses of intermediate syndrome was hence 
proposed and is presented in the following table. 
Table 4 Proposed Electrophysiological Criteria for IMS spectrum diagnosis. 
IMS spectrum Clinical weakness Electrophysiological 
changes 
None None None 
Forme fruste IMS, Stage I None  D-I at high frequencies 
Forme fruste IMS, Stage II Mild D-I at intermediate and high 
frequencies 
Forme fruste IMS, Stage III Moderate to severe D-I at all frequencies 
Forme fruste IMS, Stage IV Moderate to severe D-I and repetitive fade 
IMS Moderate to severe Severe decrement 
IMS with respiratory failure Severe with respiratory 
failure 
Severe decrement followed 
by progressive decrements. 
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Materials and Methods 
 
Type of study 
This is an observational study conducted between November 2013 to August 2014. 
Study approval 
The study was approved by the Institutional Review Board in April 2013. 
Sample Size 
The sample size calculation is based on previous studies done on Intermediate  
Syndrome and organophosphorus poisoning. The incidence of Intermediate syndrome in  
Organophosphorus poisoning is 37 % based on the study done by Dr. Lovely et.al in our 
institution in 2010. With an anticipated odd’s ratio of 4 and the study is powered to detect 
80% difference and 5 % level of significance the sample was calculated to be 169. 
Proportion of the disease                  :       0.375 
Anticipated odd’s ratio                     :       4 
Power of the study(1-beta)%           :       80 
Alpha Error                                      :       5 
Multiple correlation coefficient       :      0.41 
 
Sample size                                      :     169 
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Since the study involves detailed clinical examination with daily neurological examinations   
and electrophysiological studies , it was decided to keep a feasible sample size of 80 in this  
study. 
 
METHODS 
Patient selection 
The study participants were enrolled from the accident and emergency department,Christian  
Medical college who satisfied the following inclusion criteria. 
Inclusion criteria: 
           1 ) Age above 15 years. 
           2 ) Patients with history of consumption of organophosphorous pesticide poisoning.   
          3 ) Patients presenting within 72 hours after consumption of organophosphorous  
              compound. 
Case Ascertainment: 
1) Patients who present with alleged history of organophosphorous poisoning with an  
 
             identified compound. 
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2) Patients who present with alleged history of organophosphorous poisoning with 
 
     typical   toxidrome, and low butylcholinesterase levels. 
 
3) Patients who present without an alleged history of poisoning but with typical  
 
toxidrome of OP poisoning and low butylcholinesterase levels. 
 
Exclusion criteria: 
            All children below the age of 15 years and pregnant women. 
            Patients who have been managed in other hospitals for more than 72 hours have been                              
            have been excluded. 
Informed consent was taken for all participants after they satisfy the inclusion and exclusion 
criteria before enrolling them in the study. The recommended treatment guidelines for 
management of organophosphorus poisoning were followed.  
The baseline characters,demographic details, organophosphorus compound details ,details of 
date and time of consumption, details regarding treatment undergone in other hospitals and  
clinical profile of participant at admission in accident and emergency were recorded in the 
patient proforma. 
If the patient presented within 24 hours of consumption of the organophosphorus compound 
electromyography and nerve conduction studies were done after admission in the medical 
wards ,high dependency unit or intensive care unit. 
After admission, the participants were followed daily and clinical examination to look for 
features of encephalopathy and intermediate syndrome were recorded in the patient proforma. 
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INTERMEDIATE SYNDROME DEFINITION 
Intermediate syndrome is defined as development of proximal muscle weakness of MRC 
grading 3 or less along with extra-ocular, neck and respiratory muscles weakness developing 
after 72 hours of consumption of the organophosphorus compound, which may or may not 
require mechanical ventilation. 
Senenyake et.al were the first to describe intermediate syndrome in patients with acute 
organophosphorus consumption and they had defined intermediate syndrome as development 
of proximal muscle weakness developing 24-96 hours after the consumption of 
organophosphorus compound and after the acute cholinergic crisis has settled. 
Although Wadia had described this type of weakness in his studies as type 2 paralysis 
Senanyake had coined the term Intermediate syndrome. 
The defiintion of Intermediate syndrome used in this study has been adapted from the 
definition proposed by John and Khan,from studies which were published in our institution. 
Based on the timing of development of weakness we have divided the patients into following 
categories. 
 
Category 1 – Type 1 weakness alone 
Category 2 – Type 1 weakness followed by Type 2 weakness(Type 1-2 continuum) 
Category 3 – Type 2 weakness alone. 
Category 4 – No muscle weakness. 
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Namba scale 
Namba scale has been used widely for assessment of  severity of poisoning in patients who 
present with acute organophosphorus poisoning 
Table 5 Namba Scale 
Namba grade                                                             Clinical presentation 
Namba 1 or Latent No clinical manifestations 
Severity assessed by measurement of 
serum cholinesterase levels which is inhibited 
by 10-50 % of normal. 
Namba II or mild The patient can walk but complains of 
dizziness, headache, numbness of extremities, 
nausea and vomiting, excessive sweating and 
salivation, tightness in chest ,abdominal 
cramps or diarrhoea. 
Serum cholinesterase level is 20-50% of 
normal. 
Namba III or Moderate                                    The patient cannot walk and there is 
generalised weakness, difficulty talking, 
muscular fasciculation, miosis. 
Cholinesterase level is 10-20% of normal 
Namba IV or Severe                                         Unconsciousness, marked miosis and loss of 
pupil reflex to light, muscular fasciculation, 
flaccid paralysis, secretions from the mouth 
and nose ,moist rales in the lungs ,respiratory 
difficulty and cyanosis. 
Serum Cholinesterase levels are less than 
10% of normal. 
(Table adapted from Americal Journal of medicine, Poisoning due to organophosphate 
insecticides.Acute and chronic manifestations, 50 (4); 475-492; 1971) 
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                  Predictive scoring system 
Currently there are no treatment options available for intermediate syndrome except for 
supportive management in the form of mechanical ventilation and careful observation of the 
patient with acute organophosphorus poisoning. 
In our institution, all organophosphorus poisoning patient are observed for minimum of 5 
days after consumption. Based on the patients clinical condition they are either admitted in 
Medical high dependency unit or Semi-intensive care beds in the ward. 
In this study we have proposed to develop a predictive scoring system which would be able to 
predict the development of intermediate syndrome in patients with OP poisoning at 
admission. If we are able predict the development of intermediate syndrome on first day, the 
patients can be managed accordingly and their level of care can be ascertained at admission 
itself. 
We have formulated the predictive scoring system from a study done in our institution by 
Lovely et.al. 
The study was done to assess the risk factors for developing intermediate syndrome and the 
risk factors identified in the study were 
1) Neck muscle weakness at admission 
2) Namba scale at admission 
3) Glasgow-coma scale at admission 
4) WHO Class of organophosphorus compound 
5) Type of organophosphorus compound 
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The study had demonstrated that neck muscle weakness and Namba severity at admission 
were statistically significant risk factors for development of intermediate syndrome. 
The other risk factors were included in the formulation of the predictive scoring system even 
though they did not achieve statistical significance as the study did not have sufficient sample 
size to ascertain the statistical significance. 
Formulation of Predictive scoring system: 
In order to assess the significance of risk factors, the data from the study were re-analysed.   
Logistic regression and multivariate analysis was done on the preliminary data from the study 
done Lovely et.al. The results of the same have been shown below. The risk factors were 
analysed based on multiple logistic regression and their significance calculated.  The 
maximum score was given to neck muscle weakness as this single risk factor that was 
significantly associated with development of IMS (p value – 0.05).   
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Table 6 Multivariate analysis of risk factors 
 Odd’s ratio Confidence interval P value 
  Lower limit Upper Limit  
WHO class 1.399 0.14 13.66 0.77 
Type of  
Compound 
1.32 0.14 11.99 0.81 
Neck muscle weakness 8.29 0.99 69.45 0.05 
GCS 1.79 0.36 5.34 0.60 
Namba 4.35 0.37 51.33 0.24 
 
Table 7 Predictive scoring system 
Risk factors Maximum score Minimum score 
Muscle weakness at 
admission  
4 0 
Severity assessed by Namba 3 / 2 1 
Glasgow coma scale at 
admission 
2 1 
WHO class of compound 2 1 
Type of compound 2 1 
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Components of the scoring system: 
1) Muscle weakness at admission:  
 
Muscle weakness will be assessed clinically at admission. Muscle weakness will 
be defined as MRC grading of less than or equal to 3 in the proximal muscles or a 
poor effort to lift the neck entirely off the bed. If muscle weakness is present it 
will be given 4 points, and if absent it will be given 0 points.  
 
2) Severity assessed by Namba scale:  
 
Severity of poisoning will be assessed by Namba scale as described earlier.  
Latent             0 point 
Mild                1 point 
Moderate       2 points 
Severe            3 points 
3) Mental status  assessed by Glasgow coma scale: 
 
Altered mental status (GCS <13/15 or < 8t/15) will be given 2 points and any 
GCS better than previously mentioned will be given 1 point. 
4) WHO class of compound: 
 
WHO class I and II : 2 points 
WHO class III : 1 point 
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5) Type of compound : 
 
Di-methyl compound : 2 points 
Others : 1 point           
Maximum score at admission: 13 
Minimum score at admission:  3. 
The predictive score was calculated at the time of admission of the patient to the hospital. 
This would help in preventing potential bias of the investigator towards awarding higher 
scores to patients. 
The usefulness of the predictive scoring would be calculated using receiver operator curves 
and the sensitivity and specificity will be calculated. 
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Statistical 
Analysis 
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Statistical analysis 
Data entry was done using Epidata version 3.1.Data analysis was done using SPSS version 
16.0.Univariate and multivariate analysis was done on the data to identify risk factors and 
their significance in development of intermediate syndrome. Logistic regression was done. 
Receiver operating curve was done to assess the predictive scoring system and it association 
with the development of intermediate syndrome. 
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BASELINE CHARACTERISTICS 
The study was conducted between November 2013 and August 2014. Between this time 78 
patients were recruited into the study.  The mean age of the participants of the study was 
31.27, with slight male (63%) preponderance. We were able to identify the 
organophosphorous compound in 69 out of 78 patients. The mean pseudocholinesterase 
levels were 1845 (Lowest – 37 and Highest – 10,725) and 34 (43.5%) patients had presented 
with severe poisoning as assessed by Namba severity score. Three-fourth of the patients had 
received treatment in a local hospital before presenting to us. The most common treatments 
given were gastric lavage, pralidoxime and atropine.  
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Table 8 Baseline Characteristics 
PROFILE VALUE 
Total participants 78 
Age mean(SD) 31.27(11.97) 
Male : female ratio(percentage) 49(63%):29(37%) 
Compound identified (%) 69 (88.5%): 9 (11.5%) 
Pseudocholinestrase levels - mean 1845 
Prior treatment (%) 
 
         With Gastric Lavage 
          With Oximes 
          With Atropine 
57 (73%) : 21 (27%) 
44(56%) 
13(17%) 
28(37%) 
Severity of Poisoning        Latent 
Namba scale (%)              Mild 
                                          Moderate 
 
                                          Severe 
5(6.5%) 
17(22%) 
22(28%) 
34(43.5%) 
WHO class (% ) 
            I 
            II 
            III 
 
28(40.5%) 
31(45%) 
10(14.5%) 
Type (%) 
            Dimethyl 
            Diethyl 
            Others 
 
22(32%) 
36(52%) 
11(16%) 
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TYPE OF PARALYSIS 
 
 
 
Figure 2 Type of paralysis seen among the study patients 
 
 
 
 
 
 
ORGANOPHOSPHOROUS COMPOUND PROFILE 
 
 
 
36(46.2%) patients did not develop any weakness during hospital admission. 16 
(20.5%) patients developed only Type I paralysis which recovered. 26 (33.3 %) 
patients developed Type II paralysis.  Of these patients 22(28.2%) presenting with 
Type I paralysis persisted to have paralysis for more than 72 hours(Type I-II paralysis 
continuum). Only 4(5%) patients had developed new onset weakness after 72 hours 
without prior development of prior Type I paralysis (pure Type II paralysis).  
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ORGANOPHOSPHORUS COMPOUND PROFILE 
 
TYPE OF COMPOUND 
 
 
 
Figure 3 Different types of compounds ingested 
 
22(32%) patients had ingested an organophosphorus compound belonging to the dimethyl 
group while 36(52%) patients had ingested a diethyl compound. 11(16%) patients had 
ingested compound belonging to s-alkyl group and others. 
Rest of the 9 patients the compound was not identified. 
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WHO CLASS OF COMPOUND 
 
Figure 4 WHO class of compound 
 
85 % of the patients had ingested compounds which belonged to WHO class I(n=28) and 
WHO Class II(n=31)  while 15% of the patients had ingested compounds which belonged to 
WHO class III(n=10). Rest of the 9 patients the compound was not identified. 
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FREQUENCY OF INDIVIDUAL COMPOUNDS 
Table 9 Frequency of Individual compounds 
Compound Number WHO class Type 
Quinalphos 11 II Di-ethyl 
Monocrotophos 10 I Di-methyl 
Profenophos 10 III S-alkyl 
Chlorpyriphos 9 II Di-ethyl 
Phorate 9 I Di-ethyl 
Dimethoate 8 II Di-methyl 
Triazophos 4 I Di-ethyl 
Methylparathion 4 I Di-methyl 
Phenthoate  2 II Di-methyl 
Dichlorvas 1 I Di-methyl 
         
69 out of 78 patients enrolled in the study had the organophosphorous compound identified. 
The compound was identified if the patient/relative had recalled the name by themselves or 
some patients had either brought the leaflet of the pesticide consumed or the bottle containing 
pesticide along when they presented to accident and emergency department. The method of 
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compound identification was as follows: Name given by the patient/relative – 19.4%(n=13); 
Leaflet brought – 35.8% n=24) and Bottle brought – 44.8%(n=30). The most frequently 
ingested compounds in order of frequency were: Quinalphos, Monocrotophos, Profenophos, 
Chlorpyriphos, Phorate and Dimethoate. These 5 compounds together contributed to 82.6% 
of compounds ingested. 
TREATMENT RECEIVED IN OTHER HOSPITALS 
 
Figure 5 The details of treatment received in other hospitals 
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57(73.1%) patients had presented to a local hospital before being referred to our centre. The 
most common treatment offered were gastric lavage (77.2%), pralidoxime (23%) and 
atropine(49%). The mean duration for patients to reach a hospital for first medical treatment 
was 90 minutes (minimum duration – 10 minutes and maximum duration – 6 hours). The 
mean duration patients took to reach our centre was 5.4 hours(minimum duration  – 15 
minutes and maximum duration -2 days). 
As seen above, there is a considerable delay in patients reaching our centre for treatment. 
This is because our centre is a tertiary care hospital and hence patients are referred to our 
hospital after first line treatment in a local hospital. 
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CLINICAL OUTCOMES 
TOXIDROME AT PRESENTATION 
 
 
Figure 6 Signs and symptoms of toxidrome at presentation 
 
Most common presenting symptoms and signs at admission were were 
salivation (64%), vomiting (66.7%) and altered sensorium (43.6%). – 73 out of 
60 
 
78 patients (94%) of patients had cholinergic signs are presentation. 8 patients 
had (10.3%) had fasciculations at presentation.  
 
SEVERITY OF POISONING ASSESSED BY NAMBA SCALE 
 
Figure 7 Severity assessed by Namba scale 
 Namba severity scale was used to assess the severity of cholinergic crisis at admission. 5 
(6.8%) had no signs or symptoms (latent poisoning). 21.8 % had mild severity. The majority 
of patients (71.8%) had moderate to severe poisoning.  This reflects the profile of patients at a 
referral centre. 
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SENSORIUM ASSESSED BY GLASGOW COMA SCALE 
43(61.50%) 
14(17%) 13(17%) 
0.00%
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Figure 8 GCS at admission in non-intubated patients patients 
 
Figure 9 GCS at admission among already intubated patient 
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8 out of the 78 patients enrolled in the study were intubated outside. Above graphs depicts 
patients GCS at admission(Fig 8 – Patients who were intubated in local hospitals).Among 
patients who were intubated elsewhere 3 out of 8 patients had a GCS less than 8T/15 whereas 
5 out of the 8 patients had normal sensorium.  
Among the non-intubated patients, 61%(n=43) of the patients had presented with normal 
sensorium(GCS >13/15) and 34%(n=27) of the patients had sensorium lower than 13/15. 
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PATIENT PROFILE ACCORDING TO PUPIL SIZE AT ADMISSION 
 
Figure 10 Patient profile according pupil size at admission 
 
41% (n=32) of the patients had pupil size less than 2 mm at presentation (secondary to acute 
cholinergic crisis). 9%(n=7) of the patients presented with pupil size more than 5 
mm(probably secondary to atropine received in the primary treatment centre).50% of the 
patients had normal pupil size at presentation. 
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NECK MUSCLE WEAKNESS AT ADMISSION 
 
Figure 11 Patient profile according to neck muscle weakness at admission 
 
37(47.4%) patients had neck muscle weakness at admission while 41 patients did not have 
any features of weakness.10(12.8%) patients had fasciculations present at admission. 9 out of 
the 10 patients who had fasciculation also had neck muscle weakness. 
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NEUROLOGICAL OUTCOME 
NEUROMUSCULAR WEAKNESS 
 
TYPES OF PARALYSIS 
 
Figure 12 Distribution of patients according to types of paralysis 
 
36(46.2%) patients did not develop any weakness during hospital admission. 16 (20.5%) 
patients developed only Type I paralysis which recovered. 26 (33.3 %) patients developed 
Type II paralysis.  Of these patients 22(28.2%) presenting with Type I paralysis persisted to 
have paralysis for more than 72 hours (Type I-II paralysis continuum). Only 4 patients had 
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developed new onset weakness after 72 hours without prior development of prior Type I 
paralysis (pure Type II paralysis).  
PATTERN OF TYPE I WEAKNESS 
Type I weakness is defined as weakness which is present at admission and which resolves 
within 72 hours after consumption of the organophosphorus compound. 
The table 10  below shows the pattern of Type 1 weakness, such as neck muscle weakness at 
admission, namba severity, duration of muscle weakness and duration of mechanical 
ventilation, lowest power recorded  in the proximal muscles around the shoulder and hip, as 
assessed by MRC grade and deep tendon reflexes assessed in the knee. 
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Table 10 Description of individual patients with Type 1 weakness 
Serial 
number 
Neck 
muscle 
weakness at 
admission 
Namba 
scale at 
admission 
Duration 
of muscle 
weakness 
Duration of 
Mechanical  
ventilation 
Lowest 
Power 
Shoulder 
Lowest 
Power 
Hip 
Deep 
Tendon 
Reflex 
knee 
1 Yes Severe 1 3 4 4 2+ 
7 Yes Severe 2 4 4 4 2+ 
16 Yes Moderate 2 0 5 5 1+ 
17 Yes Moderate 2 0 5 5 1+ 
20 Yes Severe 1 2 4 4 2+ 
26 Yes Severe 1 3 4 4 2+ 
42 Yes Severe 1 5 4 4 2+ 
43 No Severe 2 2 4 4 2+ 
50 Yes Severe 1 3 5 5 2+ 
52 Yes Mild 1 2 4 4 2+ 
55 Yes Severe 2 6 3 3 2+ 
59 Yes Severe 3 3 4 4 Ab 
60 No Severe 3 4 4 4 1+ 
66 Yes Severe 2 0 4 4 2+ 
71 Yes Moderate 1 0 4 4 1+ 
72 yes Moderate 1 0 4 4 2+ 
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16(20.5%) patients out 78 patients had type I weakness. 14(88%) patients had neck muscle 
weakness at admission. 15(94%) had moderate to severe poisoning on Namba scale assessed 
at admission. The mean lowest power in upper limb was 4.07 and in the lower limb was 4.06 
. Mean duration of weakness was 1.63 days varying from 1-3 days. 11(68.8%) patients out of 
16 patients with Type I weakness required mechanical ventilation. Mean duration of 
mechanical ventilation of 2.3 days. All patients except one had intact deep tendon reflexes 
and 4 had diminished reflexes.  
 
PATTERN OF TYPE II WEAKNESS 
Type I-II continuum weakness is when the patient develops muscle weakness within the first 
72 hours of consumption and the muscle weakness persists for more than 72 hours. 
The table 11 below shows the pattern of Type I-II contiuum weakness such as neck muscle 
weakness at admission, namba severity, duration of muscle weakness and duration of 
mechanical ventilation, lowest power recorded in the proximal muscles around the shoulder 
and hip as assessed by MRC grade and deep tendon reflexes assessed in the knee. 
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Table 11 Description of Type I-II continuum weakness 
Serial 
Number 
Neck 
muscle 
weakness 
at 
admission 
Namba 
scale at 
admission 
Duration 
of muscle 
weakness 
Duration of  
Mechanical 
Ventilation 
Lowest 
Power 
Shoulder 
Lowest 
Power 
Hip 
Deep 
Tendon 
Reflex 
Knee 
77 Yes Severe 38 37 2 2 Ab 
61 Yes Severe 11 11 3 3 Ab 
22 Yes Severe 6 8 4 4 2+ 
33 Yes Moderate 5 4 4 4 1+ 
51 Yes Severe 4 3 4 4 1+ 
78 Yes Severe 10 10 3 3 2+ 
31 Yes Moderate 8 9 4 4 1+ 
73 Yes Severe 11 11 2 2 Ab 
67 Yes Severe 5 9 4 4 3+ 
12 Yes Severe 9 14 3 4 Ab 
32 Yes Severe 2 3 4 4 2+ 
3 Yes Severe 9 10 4 4 2+ 
74 Yes Severe 13 15 2 2 2+ 
41 Yes Severe 4 4 3 3 2+ 
73 Yes Severe 12 11 2 3 1+ 
25 Yes Severe 4 5 3 3 1+ 
75 Yes Severe 20 22 2 3 Ab 
79 Yes Severe 4 2 3 2 1+ 
45 Yes Moderate 4 5 3 3 Ab 
8 Yes Severe 10 14 3 3 2+ 
63 Yes Severe 5 5 3 3 1+ 
40 Yes Severe 15 18 3 4 1+ 
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22(28.2%) patients out of 78 patients had developed Type I-II continuum weakness. All the 
patients had moderate to severe poisoning. All the patients had neck muscle weakness at 
admission which persisted beyond 72 hours after consumption of OP compound. The mean 
lowest power in the upper limb was 3.04 and the mean lowest power in the lower limb was 
3.05 . Mean duration of muscle weakness was 9.2 days. All patients required mechanical 
ventilation and mean duration of ventilator days was 10.45 days. 6 patients had absent deep 
tendon reflexes and 8 had diminished reflexes. 
 
 
 
 
 
 
 
 
 
 
 
 
71 
 
PATTERN OF TYPE II WEAKNESS 
Type II weakness is described as weakness which develops 72 hours after consumption of the 
organophosphorus compound. 
Table 12 Description of individual patients with Type II weakness 
Serial 
Number  
Namba 
score 
Neck 
muscle 
weakness 
at 
admission 
GCS at  
admission 
Duration 
of 
paralysis 
Duration 
of 
Mechanical 
ventilation 
Lowest 
Power  
Shoulder 
Lowest  
Power 
Hip 
Deep 
Tendon 
Reflex 
Knee 
2 Moderate No 15/15 5 0 4 5 2+ 
27 Mild No 15/15 9 9 2 2 Ab 
53 Moderate No 11/15 9 14 3 3 2+ 
68 Moderate No 15/15 5 5 3 3 1+ 
 
 
4(5.1%) patients out 78 patients had developed muscle weakness 24 to 72 hours after 
consumption of OP compound. 3 patients required mechanical ventilation and mean 
ventilator days was 9.33 days and mean duration of muscle weakness was 7.0 days. One 
patient expired during the study period belonged to this group (cause of death was ventilator 
associated pneumonia and septic shock). 
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Table 13 Comparison between  clinical finding in Type I, I-II & II 
weakness 
 TYPE I 
WEAKNESS 
 
TYPE I-II 
WEAKNESS 
TYPE II 
WEAKNESS 
Number of patients 16 22 4 
Neck muscle weakness at 
admission (%) 
14(87.5%) 22 (100%) Nil  
Neck muscle weakness during 
course of illness (%) 
16 (100%) 22(100%) 4(100%) 
Namba scale Mild 
                       Moderate 
                       Severe 
1(6.3%) 
4(25%) 
11(68.7%) 
Nil 
3(13.6%) 
19(86.4%) 
1(25%) 
3(75%) 
Nil 
Upper limb – proximal muscle 
weakness (%) 
13(87%) 
 
 
 22(100%) 4(100%) 
Mean lowest power in the 
upper limb (SD)                
Range 
4.07(0.46) 
3 – 5 
 
3.04(0.89) 
1 - 4 
2.75(0.96) 
2 - 4 
Mean lowest power in the 
Lower limb (SD)  
Range  
4.06(0.45) 
 
3 – 5 
 
3.05(0.99) 
 
1 - 4 
2.5(1.29) 
 
1 - 4 
Mean duration of weakness in 
day in days (SD)                            
Range 
1.625 days(0.71) 
 
1 – 3 days 
 
9.5 days(7.74) 
 
4 -38 days 
 
7 days(2.3) 
 
5 – 9 days 
Mechanical Ventilation (%) 11(68.8%) 22(100%) 3(75%) 
Mean duration of  mechanical 
ventilation in days (SD)                
Range 
3.3 days(1.28) 
 
3 – 6 days 
10.45 days(7.89) 
 
2 – 37 days 
9.33 days(4.5) 
 
5 – 14 days 
Lower limb – proximal muscle 
weakness (n/%) 
13 (81.3%) 22(100%) 4(100%) 
Knee reflex – n (%)         
Proportion with diminished reflexes 
 
Proportion with Absent reflexes 
 
4 (25%) 
 
1(6.25%) 
 
8(36.4%) 
 
6(27.3%) 
 
1(25%) 
 
1(25%) 
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From the above table 13, which summaries clinical findings in patients with different types of 
paralysis we can see that type I and I-II paralysis occurs more commonly than type II 
paralysis. Neck muscle weakness was present in all patients belonging to all categories. The 
patients belonging to different types of paralysis exhibited paralysis in similar groups of 
muscles (mainly neck muscle and proximal muscle weakness).  Although the muscle groups 
affected were similar the degree of weakness was more severe in the Type II and Type I-II 
group when compared to the Type I group. Lowest power documented was lower in the Type 
II group when compared to the type I-II group which in turn was lesser than type I group. The 
Mean duration of paralysis also varied among the different groups and was longer in the Type 
II and Type I-II groups when compared to the Type I group. 
Mechanical ventilation rates were equally high in all the groups, with all patients in the type 
II group requiring mechanical ventilation. Mean duration of mechanical ventilation was 
longer in the type II and type I-II groups when compared to the type I group.  
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ENCEPHALOPATHY 
Encephalopathy is described as development of altered sensorium with a GCS of less than 
13/15 in an un-intubated patient and a GCS of less than 8T/15 in an intubated patient. 
We have divided encephalopathy as  
1) Early  - Develops at admission or within 72 hours of consumption of the  
 
organophosphorus compound. 
 
2) Delayed – Develops or persists 72 hours after consumption of the  
 
organophosphorus compound. 
 
PATTERN OF EARLY ENCEPHALOPATHY 
Early encephalopathy is described as encephalopathy which is present at admission and 
resolves by 72 hours after consumption of the compound. 
The following table 14 describes individual patients with early encephalopathy and their 
Severity of poisoning assessed by namba scale, GCS at admission, duration of 
encephalopathy, duration of mechanical ventilation and lowest GCS recorded during hospital 
stay. 
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Table 14 Description of individual patient with early encephalopathy 
Serial 
number 
Namba score GCS at 
admission  
Duration of 
Encephalopathy 
Duration of 
Mechanical  
Ventilation 
Lowest 
GCS  
78 Severe 2T 2 10 2T 
12 Severe 7T 3 14 7T 
72 Severe 3 1 2 3 
32 Severe 3 1 3 3 
3 Severe 3 1 10 3 
16 Severe 4 1 3 4 
55 Severe 4 1 5 4 
41 Severe 4 1 4 4 
60 Severe 5 1 3 4 
66 Severe 6 1 2 4T 
50 Severe 6 1 2 6 
77 Severe 7 2 37 6 
61 Severe 7 2 11 7 
1 Severe 8 1 4 7 
25 Severe 8 2 5 8 
43 Mild 9 1 2 8 
71 Severe 9 1 6 9 
52 Severe  9 1 3 11 
49 Severe 9 1 0 9 
53 Moderate 11 1 14 11 
70 Severe 11 1 0 11 
79 Severe 12 1 2 12 
19 Moderate 12 1 0 12 
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As seen in the tables 14, 23(29.5%) patients out 78 had presented with low sensorium defined 
as GCS less than 13/15(8T/15 for an intubated patient. 2(8.7%) patients among the patients 
with early encephalopathy were already intubated elsewhere in a local hospital. 20 
patients(87%) required mechanical ventilation for mean ventilators days of 7.5 days. Mean 
duration of early encephalopathy is 1.26 days. As we can see the requirement for mechanical 
ventilation was longer than the early encephalopathy duration as patients required mechanical 
ventilation for muscle weakness. (Relationship between muscle weakness and 
encephalopathy has been described in the following sections). 
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PATTERN OF DELAYED ENCEPHALOPATHY 
Delayed encephalopathy is described encephalopathy which develops or persists after 72 
hours of consumption of the OP compound. 
The following table describes individual patients with delayed encephalopathy and their 
Severity of poisoning assessed by namba scale, GCS at admission, duration of 
encephalopathy, duration of mechanical ventilation and lowest GCS documents during 
hospital stay. 
Table 15 Description of individual patient with delayed encephalopathy 
Serial 
Number 
Namba 
score 
GCS at  
admission 
Duration of 
Encephalopathy 
Duration of 
Mechanical 
Ventilation 
Lowest 
GCS 
73 Severe 2T 5 11 2T 
74 Severe 5 12 11 4T 
75 Severe 3 12 15 2T 
76 Severe 11 6 22 2T 
 
As seen in table 8, 4 patients developed delayed encephalopathy. Mean duration of delayed 
encephalopathy was 8.75 days and mean duration of mechanical ventilation was 14.75 days. 
3 out 4 patients had lowest GCS recorded as 2T/10. 
3 out of 4 patients subsequently returned to normal sensorium and were discharged alive.1 
patient was discharged against medical advice, hence the outcome of the patient is not 
known. 
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Table 16 Comparison of clinical finding in early and delayed 
encephalopathy 
 Early Encephalopathy Delayed Encephalopathy 
Frequency n (%) 23(29.5%) 4(5.1%) 
Namba    Mild (%) 
                Moderate (%) 
                Severe (%) 
 
1(4.3%) 
2(8.6%) 
20(87.1%) 
Nil 
Nil 
4(100%) 
Mean GCS at admission 
               Intubated(SD) 
               Range 
               Not intubated(SD) 
               Range 
 
4.5T (3.5) 
2T – 7T 
7.14(3.0) 
3 – 12 
 
 
2T 
Not applicable 
6.33(4.16) 
3 - 11 
Mean Lowest GCS 
               Intubated(SD) 
               Range 
               Not intubated(SD) 
               Range 
 
4.3T (2.5) 
2T – 7T 
7.1(3.2) 
3 – 12 
 
 
2.5(1) 
2T – 4T 
None 
None 
Mean duration of 
Encephalopathy(SD) 
               Range 
 
1.26 days(0.54) 
1 – 3 days 
 
8.75 days(3.77) 
5 – 12 days 
Mean duration of 
mechanical ventilation 
               Range 
 
7.1 days 
2 – 37 days 
 
14.75 days 
11 – 22 days 
 
 
 
79 
 
 
As in the table 16, comparison of early and delayed encephalopathy, the incidence of delayed 
encephalopathy is much less common when compared to early encephalopathy. The severity 
of poisoning at admission was similar between the two groups with patients predominantly 
presenting with features of severe poisoning. Sensorium assessed by Glasgow coma scale at 
admission was lower in the delayed encephalopathy group when compared to the early 
encephalopathy and the lowest GCS recorded during the illness also was lower in the delayed 
encephalopathy group when compared to the early encephalopathy group. The mean duration 
was longer in the delayed encephalopathy (Mean – 8.75 days) when compared to the early 
encephalopathy group (mean duration – 1.26 days). The duration of mechanical ventilation 
was longer in the delayed encephalopathy group (mean duration-14.71 days) as the duration 
of encephalopathy also longer in this group, when compared to the early encephalopathy 
group(mean duration – 14.75 days). 
In summary, 27 patients (%) had low GCS at admission. Of them, (23/27) % the sensorium 
normalised within 72 hours (early encephalopathy).  However in (4/27)% the sensorium 
continued to be depressed for a variable duration. It appears that delayed encephalopathy, in 
patients who have a prior normal sensorium did not occur in the study group. 
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TEMPORAL PROFILE OF PARALYSIS AND ENCEPHALOPATHY 
 
TEMPORAL PROFILE OF EARLY ENCEPHALOPATHY AND PARALYSIS 
The following table 17, compares individual temporal profile of paralysis and encephalopathy 
with GCS at admission, encephalopathy duration, type of paralysis, paralysis duration, lowest 
GCS recorded and lowest power in the proximal muscles around the shoulder and hip. 
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Table 17 Temporal profile of individual patients with early encephalopathy 
and paralysis 
 
 
Serial 
Number 
 
 
 
GCS  
at 
admission 
Duration of  
Encephalo-pathy 
 
Type  
of 
Paralysis 
Duration of 
Paralysis 
 
Lowest 
GCS 
Lowest 
Power 
Shoulder- 
Hip 
78 2T 2 Type I-II 10 2T 2  -  1 
12 7T 3 Type I-II 9 7T 3  -  3 
72 3 1 Type I 1 3 4  -  4 
32 3 1 Type I-II 2 3 4  -  4 
3 3 1 Type I-II 9 3 3  -  3 
16 4 1 Type I 1 4 5  -  5 
55 4 1 Type I 1 4 3  -  3 
41 4 1 Type I-II 4 4 4  -  4 
60 5 1 Type I 1 4 4  -  4 
66 6 1 Type I 2 4T 4  -  4 
50 6 1 Type I 1 6 5  -  5 
77 7 2 Type I-II 38 6 1  -  1 
61 7 2 Type I-II 5 7 3  -  3 
1 8 1 Type I 2 7 4  -  4 
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 Temporal profile of individual patients with early encephalopathy and paralysis 
(Table continued) 
 
Serial 
Number 
GCS  
at 
admission 
Encephalo-pathy 
Duration 
Type  
of 
Paralysis 
Paralysis 
Duration 
Lowest 
GCS 
Lowest 
Power 
Shoulder- 
Hip 
25 8 2 Type I-II 4 8 3  -  3 
43 9 1 Type I 1 8 4  -  4 
71 9 1 Type I 2 9 4  -  4 
52 9 1 Type I 3 11 4  -  4 
49 9 1 Nil 0 9 5  -  5 
53 11 1 Type II 9 11 2  -  2 
70 11 1 Nil 0 11 0  -  0 
79 12 1 Type I-II 4 12 2  -  2 
19 12 1 Nil 0 12 5  - 5 
 
23(29.5%) patients out of 78 patients had early encephalopathy only. 3(13%) patients did not 
have any neuromuscular weakness whereas 20 patients had weakness which lasted for 
varying duration. Mean duration of encephalopathy was  1.26 days with a maximum of 3 
days  and minimum if of 1 day of encephalopathy. Mean duration of paralysis was 5.45 days. 
Mean power in the upper limb was lower limb was 3.3. 
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TEMPORAL PROFILE OF DELAYED ENCEPHALOPATHY AND PARALYSIS 
Table 18 Temporal profile of individual patients with delayed 
encephalopathy and paralysis 
 Early  
Encephalopathy 
IMS Encephalopathy 
Duration 
Paralysis 
Duration 
Lowest 
GCS 
Lowest  
power 
Patient 
1 
2T/10 Yes Day 1 – 10 Day 1 -11 2t/10 UL-2/5 
LL-2/5 
Patient 
2 
5/15 Yes Day 1- 12 Day 1 -12 4T/10 UL-3/5 
LL-3/5 
Patient 
3 
3/15 Yes Day 1 – 12 Day 1- 12 2T/10 UL-4/5 
LL-4/5 
Patient 
4 
11/15 Yes Day 10- 15 Day 1 - 20 2T/10 UL-2/5 
LL-3/5 
 
4(5.1%) patients out of 78 patients had encephalopathy which present beyond 72 hours after 
consumption of OP compound. All four patients had low sensorium at admission and 3 
patients had persistent low sensorium which required varying duration of mechanical 
ventilation. 
Mean duration of encephalopathy was 9.75 days and mean duration of paralysis was 13.75 
days. All four patients with delayed encephalopathy also demonstrated Type I-II continuum 
weakness. 3 patients recovered completely and were discharged alive and well while 1 patient 
was discharged against medical advice, hence the outcome of the patient was not known. 
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Table 19 Comparison between clinical finding of early and delayed 
encephalopathy. 
 Early encephalopathy Delayed encephalopathy 
Type I paralysis (%) 10 (43.5%) Nil 
Type I – II paralysis (%) 9 (39%) 4 (100%) 
Type II paralysis (%) 1 (4.5%) Nil 
No weakness 3 (13%0 Nil 
Mean lowest muscle power 
in  
Shoulder(SD) 
Range 
 
3.3 (1.3) 
0 – 5 
 
 
2.75(0.95) 
2 - 4 
Mean lowest muscle power 
in  
Hip(SD) 
Range 
 
3.3 (1.3) 
0 - 5 
 
 
3(0.81) 
2 - 4 
Mean duration of paralysis 5.45 days 13.75 days 
Mean duration of 
Encephalopathy 
1.26 days 9.75 days 
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The table 19 above summarises the temporal profile of paralysis among early and delayed 
encephalopathy.  
Entire spectrum of paralysis is seen among the patient with early encephalopathy. Type I 
paralysis and Type I-II continuum paralysis occurs almost equally accounting for 83% of the 
patients with paralysis. Type II paralysis is seen in only 1 patient with early encephalopathy. 
Patients with delayed encephalopathy exhibit only Type II paralysis. 
The mean lowest power in the upper limb and lower  limb are lower in the delayed in the 
delayed encephalopathy group when compared to the early encephalopathy. 
The two groups mainly differ in the duration of paralysis with duration of paralysis being 
prolonged in the delayed encephalopathy group. The duration of mechanical ventilation and 
encephalopathy is longer in the delayed encephalopathy as the patients require prolonged 
ventilatory support till the sensorium recovers. 
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PATTERN OF PARALYSIS AND ENCEPHALOPATHY AMONG 
INDIVIDUAL ORGANOPHOSPHORUS COMPOUNDS 
Table 20 - Pattern of Paralysis and encephalopathy with individual OP 
compounds. 
 Quinalphos Monocrotophos Profenophos Chlorpyriphos Phorate 
Frequency 11 10 10 9 9 
No weakness 
(%) 
 
5 (45.5%) 5(50%) 4(40%) 7(77.8%) 5(55.5%) 
Type I weakness 
(%) 
3(27.3%) 2(20%) 3(30%) Nil 2(22.2%) 
Type I-II 
Weakness (%) 
3(27.3%) 3(30%) 2(20%) 1(11.1%) 2(22.2%) 
Type II 
Weakness (%) 
Nil Nil 1(10%) 1(11.1%) Nil 
Early 
Encephalopathy 
(%) 
3(27.3%) 3(30%) 2(20%) 1(11.1%) 2(22.2%) 
Delayed 
Encephalopathy 
(%) 
Nil Nil Nil Nil 1(11.1%) 
Mean duration 
of Paralysis(SD) 
6 days 
(4.2) 
9.33 days 
(5.03) 
6 days 
(5.8) 
6 days 
(4.25) 
2 days 
(1.73) 
Mean duration 
of 
Encephalopathy 
 
1.25 days 
 
 
1.67 days 
 
1 day 
 
1 day 
 
 
4.67days 
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The above table describes different types of weakness and encephalopathy among 5 most 
common types of organophosphorus compounds in our study. The rates of different types of 
paralysis are nearly equal among the different types of compounds. The rates of early 
encephalopathy seem to be equal among the compounds. The mean duration of paralysis is 
longer among the patient with monocrotophos and phorate group.  From this comparison we 
can see the incidence of paralysis and encephalopathy are equal among different compounds 
with the duration of paralysis and encephalopathy prolonged among the Monocrotophos 
group. 
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DURATION OF HOSPITAL STAY 
 
Figure 13 Duration of Hospital stay 
 
Mean duration of hospital stay among patients who had no weakness was 5.6 days(SD-1.6). 
Mean duration of hospital stay in Type I weakness was 6.75 days (SD-1.39).Mean duration of 
hospitalisation in Type I-II continuum weakness was 18.09 days(SD-11.78). Mean duration 
of hospitalisation in Type II weakness 13.75 days(SD-4.5). The results suggest that the 
presence of paralysis and duration of paralysis prolong the duration of hospitalisation 
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MECHANICAL VENTILATION 
Figure 14 Duration of mechanical ventilation 
 
31 patients out of 78 patients with no weakness and 5 patients with Type I weakness did not 
require any mechanical ventilation.  10 patients with type I weakness, 8 patients with Type I-
II continuum weakness, 1 patient with Type II weakness required mechanical ventilation less 
than 5 days. 1 patient with Type I weakness, 5 patients with Type I-II continuum weakness 
and 1 patient with Type II weakness required ventilation between 6 to 10 days. 7 patients 
with Type I-II weakness and 1 patient with Type II weakness required mechanical ventilation 
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between 11 to 20 days.  2 patients with Type I-II continuum weakness required mechanical 
ventilation for 22 days and 37 days.   
HOSPITAL OUTCOME 
Figure 15 Outcome of patients at discharge 
 
74 patients (94.9%) were discharged alive and well. 3 patients were discharged at request and 
1 patient died during treatment due to ventilator associated pneumonia and septic shock. 
 
 
 
 
 
91 
 
PREDICTORS OF INTERMEDIATE SYNDROME 
The predictors of Intermediate syndrome that were assessed in this study are 
1) WHO class of compound 
 
2) Type of Compound 
 
3) Neck muscle weakness at admission 
 
4) GCS at admission 
 
5) Namba score at admission 
 
6) Pseudocholinesterase 
 
1) WHO CLASS OF COMPOUND 
 
 
Table 18 WHO class of compound and Intermediate syndrome 
 
    NO IMS IMS 
WHO CLASS I             n 
              %              
19 9 
68% 32% 
II            n 
              %              
22 9 
71% 29% 
III           n 
              %              
7 3 
70% 30% 
Pearson chi-square test – 0.743 
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In order to calculate the significance of WHO class of compound, patients with WHO class I 
and II compound poisoning were considered to have a higher chance of developing IMS. But 
the difference was not statistically significant. 
 
2) TYPE OF ORGANOPHOSPHORUS COMPOUND 
 
Table 19 – Type of compound and Intermediate syndrome 
    No IMS IMS 
TYPE Dimethyl     n 
                  % 
18 7 
72% 28% 
Diethyl        n 
                  % 
23 10 
69.7% 30.3% 
S Alkyl         n 
                  % 
7 4 
63.4% 36.6% 
Pearson chi-square test – 0.465 
 
The prevalence of Intermediate syndrome was nearly equal in the different type of 
compounds (dimethyl, diethyl and s-alkyl) and we did not demonstrate a statistically 
significant co-relation between the type of compounds and development of IMS. 
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3) NECK MUSCLE WEAKNESS AT ADMISSION 
 
 
Table 20 Neck muscle at admission and Intermediate syndrome 
   
56.7% of patients who had weakness at admission, went onto to develop IMS compared 9.8% 
of those who had no muscle weakness at admission. Neck muscle weakness assessed at 
admission was found to be a risk factor which was significantly associated development of 
IMS (p=0.001). 
 
 
 
 
 
 
    NO IMS IMS 
WEAKNESS  YES        n 
             % 
16 21 
43.3% 56.7% 
NO         n 
             % 
37 4 
90.2% 9.8% 
Pearson chi-square test – 0.001 
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4) GLASGOW COMA SCALE 
 
 
Table 21 Glasgow coma scale at admission and Intermediate syndrome 
 
    NO IMS IMS 
GCS  >/=13       n 
>/= 8T     %               
40 12 
% 30.4% 
<13           n 
<8 T        % 
13 13 
52.9% 47.1% 
Pearson chi-square test – 0.016 
 
 
47.1% of patients who presented with low GCS (<13 in non-intubated patients and <8 in 
intubated patients) went onto develop IMS compared to 30.4% in patients who normal GCS 
(>13 in non-intubated patients and >8 in intubated patients). Low Glasgow coma scale 
assessed at admission was found to be significantly associated with development of IMS 
(p=0.016) and maybe a risk factor for development of IMS. 
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5) SEVERITY OF POISONING ASSESSED BY NAMBA SCALE 
 
Table 22 Severity of poisoning (Namba scale) and Intermediate syndrome 
 
 
 
 
 
 
 
 
 
In order to calculate the significance of Namba scale as a risk factor for developing IMS, 
Latent and mild poisoning were coupled together and were compared with patients with 
moderate and severe poisoning. No patient with latent OP poisoning and 6% of patients 
with mild OP poisoning (1 of 16 patients) developed IMS compared to 27.3% of those 
with moderate and 53% with severe poisoning. Moderate and severe poisoning were 
significantly more likely to develop IMS than latent and mild poisoning (p=0.001). 
 
 
 
 
 
 
    NO IMS IMS 
NAMBA 
SCALE 
LATENT            n 
                       % 
5 0 
100.0% .0% 
MILD               n 
                       % 
16 1 
94% 6% 
MODERATE      n 
                       % 
16 6 
72.7% 27.3% 
SEVERE           n 
 
                       % 
16 18 
47% 53% 
Pearson chi-square – 0.001 
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6) PSEUDOCHOLINESTRASE 
 
Pseudocholinesterase is continuous variable, hence it was evaluated by Mann-Whitney test to 
as significance and median. 
Table 23 Pseudocholinestrase and intermediate syndrome 
 IMS Frequency Median Minimum Maximum 
Pseudocholinestrase No 53 266 37 10,725 
 Yes 25 116 40 3457 
 
The mean Pseudocholinestrase value in patients who developed IMS was 729.42 U/L 
compared to 3399.87 U/L in those who did not develop IMS and this was statistically 
significant (p+0.002). A normal BuChE at admission appears to predict that patients will not 
develop IMS and a low BuChE level appears to a risk factor for development of IMS  
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MULTIVARIATE ANALYSIS OF RISK FACTORS FOR INTERMEDIATE 
SYNDROME 
The risk factors which were analysed by univariate analysis and the risk factors which had 
significance of more than 25 % were taken for multivariate analysis. 
The following risk factors were assessed by multivariate analysis. 
1) Neck muscle weakness at admission 
 
2) Glasgow coma scale at admission 
 
3) Severity assessed by Namba scale 
 
4) Serum pseudocholinesterase levels done at admission 
 
5) Type of Compound 
 
6) WHO class of compound 
 
 
Table 24 Multivariate analysis of risk factors of IMS. 
 Chi-
square 
test 
P value Odd’s ratio Confidence interval 
 Lower 
limit 
Upper 
limit 
WHO class 0.74 0.47 0.67 0.23 1.98 
Type of  
Compound 
0.47 0.74 0.84 0.29 2.45 
Neck muscle 
weakness 
0.001 0.005 7.87 1.86 33.40 
GCS 0.02 0.64 1.38 0.36 5.34 
Namba 0.001 0.57 1.78 0.25 12.77 
Pseudocholinesterase  0.016 0.28 0.10 0.79 
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The risk factors which were significant in the univariate analysis (GCS, Namba scale and 
neck muscle weakness at admission) were analysed in the multivariate analysis. 
Neck muscle weakness was found to be significantly associated with development of 
Intermediate syndrome(p – 0.005;OR – 7.87;CI – 1.86 – 33.4).  Pseudocholinesterase levels 
also achieved statistical significance after multivariate analysis (p – 0.016;OR- 0.28;CI – 0.10 
-0.790. Glasgow coma scale (p -0.64;OR – 1.38;CI – 0.36 - 5.34) and Namba scale(p – 
0.001;OR – 1.78;CI - 0.25 – 12.77)  which were significant in the univariate analysis lost 
their significant in the multivariate analysis. 
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PREDICTIVE SCORING SYSTEM 
The Predictive scoring system was formed from a previous study which evaluated the risk 
factors for intermediate syndrome. 
Components of Predictive scoring system: - 
Table 25      Predictive score system  
Risk factors Maximum score Minimum score 
Muscle weakness at 
admission  
4 0 
Severity assessed by Namba 3 / 2 1 
Glasgow coma scale at 
admission 
2 1 
WHO class of compound 2 1 
Type of compound 2 1 
 
 
The correlation between the scores and development of intermediate syndrome was done 
using receiver operating characteristics curve and results are as follows.  
 
 
 
 
100 
 
 
 
 
Figure 16 ROC curve - Predictive socring system 
Area under the curve – 0.784 
Standard error – 0.053 
Confidence interval – 0.68 to 0.88
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Table 26 Sensitivity and Specificity for predictive score 
Score Sensitivity Specificity 
2.00 1.000 0.000 
3.50 1.000 0.019 
4.50 1.000 0.094 
5.50 0.958 0.377 
6.50 0.917 0.547 
7.50 0.917 0.660 
8.50 0.875 0.679 
9.50 0.792 0.717 
10.50 0.583 0.755 
11.50 0.375 0.811 
12.50 0.208 0.962 
14.00 0.000 1.000 
 
The area under the curve was calculated to be 0.784, which indicates the test being evaluated 
is a fairly good test for assessing patients who may develop intermediate syndrome. The 
sensitivity and specificity for individual scores were calculated by plotting the area under the 
curve and the values are presented in the table above. 
The test performs best for a score of 9.5 with sensitivity of 79.2% and specificity of 71.7%. 
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In order to test the scoring system the score with best sensitivity and specificity and two more 
scores – 1 score above the best score and 1 score below the best score was taken and the 
individual Sensitivity, specificity, positive predictive value, negative predictive value, 
likelihood rations and post-test probabilities were calculated. 
Table 27 Post-Test probability for individual predictive scores 
Score Sensitivity Specificity PPV NPV Likelihood 
ration 
Post-test 
Probablity 
8.5 87.5 67.92 55.26 92.31 2.73 55% 
9.5 79.17 71.70 55.88 88.37 2.8 56% 
10.5 58.33 75.47 51.85 51.85 2.38 52 
 
Table 28 Cross tabulation of predictive score and intermediate syndrome 
Score 3 4 5 6 7 8 9 10 11 12 13 
IMS-
Yes 
0 0 1 1 0 1 2 5 5 3 6 
IMS- 
No 
1 3 15 10 6 1 2 2 3 8 2 
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The predictive score at a score of 8 has a Sensitivity and specificity of 87.5% and 67.9% and 
Positive and negative predictive value of 55.2% and 92.3%. Among the patients in this study, 
55% (22/40) with admission score >8 developed IMS compared to 5% (2/37) with score <8. 
For a patient to have a score of 8 based on clinical criteria, they would have neck muscle 
weakness (score of 4), moderate or severe poisoning (score of 2 or 3) with GCS <13 (score of 
2). A combination of all these clinical criteria, a patient has 55.2% likelihood of developing 
IMS. In the absence of any or all of these, the likelihood of developing IMS falls to 5%.  
Hence with high sensitivity and high negative predictive value at a cutof score of 8, the 
scoring system can be a good tool to rule out patients who will not develop intermediate 
syndrome.  
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                             DISCUSSION 
 
CLINICAL PROFILE AT ADMISSION 
78 patients were enrolled in our study to assess the temporal profile of encephalopathy and 
paralysis in patients who present with acute organophosphorus poisoning.  
Incidence of Intermediate Syndrome 
The incidence of Intermediate syndrome in our study was 33.4%. This rate was similar to 
earlier reports of incidence of intermediate syndrome reported from our institution that have 
varied from 37.5% (Lovely et al) and 47% in a study done by Peter et al.(10). However the 
incidence of Intermediate syndrome in published literature had been varied. , In contrast in a 
study done by Jayewardene at al in Sri Lanka reported the incidence of 11.5%. This may have 
been due to restriction of WHO class I compounds in Sri Lanka(20). However other studies 
from India have also reported lower incidences (Indira et al reported 17.6% incidence).(21)  
Background characteristics and clinical profile 
The background profile of OP poisoning in this study was similar to earlier descriptions, 
affecting the young adults (between 15-30 years), predominantly men and chiefly due to 
deliberate self harm (10)(22). The majority of patients were moderate to severely poisoned 
reflecting the high rates of cholinergic symptoms of salivation, vomiting and altered 
sensorium.Similarly three-fourth of the patients had received treatment in a local hospital 
before presenting to our hospital including gastric lavage, atropine and oximes reflecting the 
referral pattern of severely poisoned patients to our hospital.  
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Type of Organophosphorus poison consumed 
As in earlier studies we were able to identify the OP compound in the majority of patients 
based on the history and the poison container brought with the patient. 88% patients had 
poisoning with an identified organophosphorus compound and the most common consumed 
compounds were Quinalphos (n=11, Monocrotophos (n=10) and Profenophos (n=10), 
Chlorpyriphos (n=9), Phorate (n=9). Four of the five most commonly consumed poisons were 
Class I and Class II compounds.. The distribution of type of compounds (Dimethyl-32%, 
Diethyl-52%) and WHO class (Class I-40.5%, Class II-45%) of compound among the 
identified were represented equally. These results are similar to the study by Lovely et al and 
indicate the predominant poison with highly toxic Class I and Class II OP compounds and the 
free access of these compounds in the Indian market and to the local community. The 
identification of compounds in the majority of case made it possible for us to study the 
association between specific compounds and the development of Intermediate syndrome.  
Clinical profile of muscle paralysis in organophosphate poisoning 
About half the patients did not develop any muscle paralysis. Of the other half, 20.5% 
developed early paralysis (Type I paralysis) and about 33.3% developed early paralysis that 
persisted beyond 72 hours (Type I and Type II paralysis continuum).  Only a minority of 4 
patients developed new onset weakness after 72 hours (pure Type II paralysis).  
The analysis of the clinical features of muscle paralysis between Type I and Type I and II 
paralysis continuum in our study suggests that the main difference between these two is the 
severity of weakness and the duration of weakness. 
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These confirm the concept suggested by Mathew(14), Avasthi(19) and Jayawardane et al(20), 
that Type I and Type II paralysis are not separate clinical entities but that there is a 
continuum of the same paralysis. Patients with mild poisoning do not develop any paralysis. 
Patients with moderate to severe poisoning may develop muscle paralysis which recovers 
(Type I paralysis) or may continue to be paralysed for a longer period after the cholinergic 
signs improve (Type II paralysis). The chief determinant of whether a patient develops Type I 
or Type II paralysis appears to be the severity of poisoning.   
Risk factors for the development of intermediate syndrome 
Relationship between Type of OP compound, WHO class and specific compounds and 
intermediate syndrome. 
In our study we found that the rates of IMS did not vary between WHO compound class, 
dimethyl and diethyl compounds and between most commonly ingested compounds. There 
was no statistical correlation between the type of compound and development of intermediate 
syndrome.(p value – 0.47) and between WHO class and development of Intermediate 
syndrome.(p value – 0.74).) This is in contrast to earlier studies have also shown that 
poisoning with organophosphorus compounds belonging to WHO class I and II had a higher 
chance of developing intermediate syndrome (2). Studies by Peter et al demonstrated that 
dimethyl compounds had a higher chance of developing intermediate syndrome (10).  
Senenayake also found association between specific compounds and the development of 
intermediate syndrome in his initial descriptions(23).  
The results of our study suggest that IMS is class independent and compound independent 
complication of acute organophosphorus poisoning. 
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Severity of poisoning and the development of intermediate syndrome 
In our study neck muscle weakness assessed at admission was found to be a significant risk 
factor for development of intermediate syndrome. (p – 0.005; CI 1.8 to 33.4). Sensorium 
assessed by Glasgow coma scale at admission and severity assessed by Namba scale were 
significantly associated with the development of intermediate syndrome.(p – 0.016 and p 
value – 0.001 respectively). Similar conclusions were drawn from a study done by Indira et al 
and she had described  age more than 45 years, neck muscle weakness and poisoning severity 
score of more than 2 was associated with higher chance of developing respiratory failure.(21) 
Pseudocholinestrase levels measured at admission correlated well with development of 
intermediate syndrome (p value – 0.02). Although the results for pseudocholinestrase as a 
risk factor for development of IMS are varied, Avasthi et al and Shailesh et al, in their studies 
have demonstrated an association between the same. Hence our study suggests that severe 
inhibition of pseudocholinesterase should provide a clue to the clinician to carefully monitor 
patients for the development of IMS (22)(19). 
Although GCS and severity assessed by Namba scale had significant association with the 
development of IMS, after logistic regression and multivariate analysis, they failed to show 
significant correlation. This finding could be explained by the fact that the two risk factors 
may be related and hence the statistical significance is lost when combined in the multivariate 
analysis. The inter-relationship between parameters severity of poisoning, low GCS and neck 
muscle may be confounding their individual relation to IMS in a logistic regression analysis. 
Nevertheless neck muscle weakness assessed at admission, GCS at admission and Severity of 
poisoning assessed by Namba scale can individually be used as a risk factor for prediction of 
intermediate syndrome in patients with acute organophosphorus poisoning. The analysis 
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seems to suggest that the most important pathogenetic factor leading to the development of 
IMS is a high poison load that causes central and peripheral Acetylcholinesterase inhibition 
manifesting with features of severe poisoning (cholinergic signs), low GCS and neck muscle 
weakness. The IMS appears to be class and compound independent phenomenon related to 
the severity of poisoning and the severity of Acetylcholinesterase inhibition. 
CENTRAL AND PERIPHERAL NEUROMUSCULAR MANIFESTATIONS OF OP 
POISONING 
Two most common complications of organophosphorus poisoning are muscle weakness and 
encephalopathy. Although various studies have described intermediate syndrome but there 
have been no prospective studies which have described them together. Peter et al in a 
retrospective study described delayed encephalopathy as altered sensorium developing after 
72 hours of consumption of the toxin. In our study, early paralysis (Type I weakness) was 
seen in 16(20.5%) patients. Delayed paralysis (Type I-II and Type II weakness) was seen 
26(33%) patients. 
Early encephalopathy was seen in 23 patients (29.5%) and delayed encephalopathy, that is 
low sensorium developing after 72 hours after consumption or persisting low sensorium 
beyond 72 hours, was seen in 4(5%) patients. Early encephalopathy has been described in the 
history of acute organophosphorus poisoning by Wadia et al and it is well known that early 
encephalopathy can be caused by multiple factors such as toxic delirium secondary to the 
organophosphorus compound, central receptors dysfunction due the toxin or maybe 
secondary to atropine toxicity itself. Early encephalopathy has good response to treatment 
with atropine and resolves within a few days. In our study, patients with early encephalopathy 
had a mean duration of 1.26 days for recovery of altered sensorium and required mechanical 
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ventilation for a short duration as a supportive treatment during the recovery period (Mean 
ventilator days – 7.5days). The majority of patients with early encephalopathy had early 
muscle weakness (10(43.5%) patients with early encephalopathy among 23 patients who had 
early encephalopathy also had early type I paralysis). 
Patient who had persisting low sensorium beyond 72 hours required prolonged ventilation 
(mean ventilator days – 14.75 days). All four patients who developed delayed encephalopathy 
also developed muscle weakness of varying duration (duration of muscle weakness – 13.75 
days). The delayed encephalopathy and muscle weakness were coincident and parallel which 
suggests that similar mechanisms may be involved in both clinical phenomena. Hence we 
propose a similar mechanism which mediates intermediate syndrome maybe involved in 
patients who develop delayed encephalopathy. 
These results appear to suggest that encephalopathy and muscle weakness are coincident 
manifestations of the same syndrome. There are three patterns of the relationship between 
encephalopathy and muscle weakness. In the early phase of severe poisoning, most patients 
have encephalopathy and muscle weakness. In the first pattern, encephalopathy and muscle 
weakness both recover in 72 hours (40%) which takes place in Type I paralysis. In the second 
pattern, encephalopathy recovers but the muscle weakness persists (40% of patients) which 
takes place in Type II paralysis. In third pattern which occurs in a minority of patients 
encephalopathy and muscle weakness persist and recover together, which is the Type II 
paralysis (IMS) with encephalopathy. We therefore suggest that the term, Delayed 
organophosphate encephalopathy (DOPE) (16)or CNS intermediate that has been proposed in 
earlier studies of encephalopathy may not be appropriate, as this syndrome appears to be part 
of the intermediate syndrome rather than a separate clinical syndrome. We suggest instead the 
term Intermediate-encephalopathy syndrome (IMES), where a minority of patients with IMS 
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have persisting encephalopathy with potential for good neurological recovery.  Just as Type I 
and Type II paralysis (IMS) appear to part of continuum of paralysis, similarly early and 
delayed encephalopathy also appear to be a continuum of low GCS and the paralysis 
invariably occurs as part of the entire syndrome. 
 
 
Probable mechanism of Encephalopathy – A hypothesis 
Early encephalopathy is mediated by toxic effects of the organophosphorus compound and 
the dysfunction caused in the synapses in the central nervous system receptors (muscarinic 
and nicotinic receptors) and the altered sensorium responds well to treatment with atropine. 
On the other hand, atropine has no effect on delayed encephalopathy. Hence the mechanism 
of delayed encephalopathy must be a unique process and may be due to persistent inhibition 
of nicotinic receptors or downstream events at the cellular level. 
In our study we have demonstrated that encephalopathy and persistent neuromuscular 
weakness are coincident in patients with acute organophosphorus poisoning and part of the 
same syndrome. Numerous mechanisms have been postulated for development of 
intermediate syndrome.  Role of acetylcholinesterase inhibition and excessive stimulation by 
acetylcholine in the neuronal junction in the peripheral as well as central neuronal junctions 
have been studied in human and animal models.(24) Inhibited acetylcholinesterase 87% in 
striatum, 67% in hippocampus, 58% in cerebellum in rats that have been poisoned with 
monocrotophos, Hence the excessive and prolonged suppression of acetylcholinesterase 
enzyme in the central neuronal junctions may lead to the persistent altered sensorium. 
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The role of oxidative stress has been implicated in the progression of type I paralysis to type 
II paralysis and severely poisoned patients have a higher degree of oxidative stress and hence 
have higher chance of developing type II paralysis(25)(26).  In our study we have seen that 
patients who present early encephalopathy the sensorium remains depressed in certain 
individuals, which parallels the progression of Type I paralysis to Type I-II continuum 
paralysis. In the rat model of monocrotophos poisoning significant lipid peroxidation and 
antioxidant enzymes were induced 8h after poisoning, directly correlated to high  
acetylcholinesterase inhibition (>67%) in all areas of the brain. Recovery from 
monocrotophos poisoning was associated with absence of lipid peroxidation in the brain 
although acetylcholinesterase inhibition persisted. In this study it was suggested that 
neurotoxicity of monocrotophos poisoning is characterized by 
oxidative damage in regions of the brain that exhibit high acetylcholinesterase 
activity and severe acetylcholinesterase inhibition and that recovery from poisoning is 
associated with prolonged induction of antioxidants that protect against 
oxidative damage. Whether oxidative stress plays a role in the mechanism of persisting low 
sensorium is a hypothesis which needs to be considered and further studies are needed. 
Role of muscle injury and post synaptic structure have been postulated in the development of 
intermediate syndrome.(27)(28) In a study published in our institution, muscle enzymes were 
enzymes measured serially and it was observed that muscle injury was present at admission 
and it peaked at 5 days and decreased over the next 5 days.(14) The temporal profile of 
encephalopathy and paralysis seen in our study parallels a similar course, hence the role of 
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post synaptic structures acting at a sub-cellular level should be considered in the mechanism 
of persistent encephalopathy. 
Inhibition of mitochondrial ATP synthase, decreased mitochondrial uptake of calcium and 
increased levels of nitric oxide with altered mitochondrial bioenergetics has been implicated 
in muscle paralysis in rat model of monocrotophos poisoning. (29)  Energy is critical to 
muscle and it has been suggested that increased demand for energy and failure of energy 
supply may underlie muscle weakness in Intermediate syndrome. The brain too requires high 
energy levels. Since muscle weakness and encephalopathy occurs together and parallel each 
other, it is likely that there are similar mechanisms that operate downstream of 
acetylchoinesterase inhibition. Whether there are similar mechanisms to those that occurs in 
muscle weakness that operate in the brain, leading to ATP synthase inhibition and increase in 
the nitric oxide levels causing persistent encephalopathy is a possible direction for further 
study. 
In our study we have demonstrated that all patients who developed delayed encephalopathy 
also developed intermediate syndrome but the frequency of delayed encephalopathy was seen 
much less common than intermediate syndrome.(Incidence of Intermediate syndrome – 
33.3% and Delayed encephalopathy - 5.1%). The same observation was made by Peter et al 
when they had described delayed onset encephalopathy(16). Although the mechanisms of 
persistent encephalopathy are still unknown, there seems to be an underlying mechanism 
which makes it a rarer manifestation of acute organophosphorus poisoning when compared to 
type 2 paralysis. As we have proposed earlier in the discussion that intermediate syndrome 
and persistent encephalopathy might have a similar mechanism, there might a protective 
factor which prevents persistent encephalopathy from occurring. Animal studies show that 
induction of anti-oxidant mechanisms and cytoprotection may determine central nervous 
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system recovery after monocrotophos poisoning.  We hypothesise that there is a failure of a 
central cytoprotective mechanism that leads to persistent encephalopathy.  
In summary our hypothesis is that persistent acetylcholinesterase inhibition underlies both the 
intermediate syndrome and encephalopathy syndrome. Mechanisms similar to those that 
occurs in intermediate syndrome in muscle of oxidative stress and altered mitochondrial 
bioenergetics may also occur in the brain leading to encephalopathy. The failure of central 
antioxidant and cytoprotective mechanisms may lead to persistent encephalopathy in a 
minority of patients. This hypothesis offers direction for further research work into the 
mechanisms of  the Intermediate-Encephalopathy syndrome. 
NOTE ON PREDICTIVE SCORING SYSTEM 
 
Intermediate syndrome is the most common complications and till date there is no effective 
treatment nor a tool to predict which patient will develop the complication. As the 
complication can arise 24 to 96 hours after the toxin consumption all patients with acute 
organophosphorus poisoning are observed in the hospital for a minimum of 5 days before 
discharge.(30) Studies have been conducted to predict the mortality associated with acute 
organophosphorus poisoning.  Numerous studies have assessed generic scoring system such 
as International Program on Chemical Safety Poison Score (IPC PSS), Glasgow coma 
scale(31), Acute Physiology and Chronic Health Evaluation (APACHE) , Mortality 
Prediction Model (MPM) II , Simplified Acute Physiology Score(SAPS) II and Poisoning 
Severity Score (PSS)(32)  to predict early neck muscle weakness which help in identifying 
patients  who may require respiratory failure and mortality among organophosphorus 
poisoning patients.  A score of above 2 in the IPC PSS and a low GCS can predict early 
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respiratory failure,(21) In a retrospective study done, APACHE II score and SAPS II score 
performed better than PSS and has been suggested to predict mortality in patients with acute 
organophosphorus poisoning. But in our study we have developed a predictive tool which can 
assist in emergency triage of patients to predict patients who have a lower chance of 
developing intermediate syndrome and can be managed safely in the ward or probably can be 
discharged from the ward earlier than 5 days. 
Although numerous tools have been assessed for mortality prediction, this is the first time a 
tool for prediction on intermediate syndrome has been formulated. The predictive tool 
included sensorium assessed by Glasgow coma scale, Severity of poisoning assessed by 
Namba scale, type and WHO class of compound and neck muscle weakness assessed at 
admission. The predictive score performed well with area under the curve of 0.784 and 
sensitivity and specificity of 79% and 72% respectively. The positive predictive value 
negative predictive values were 56% and 92% respectively. 
The predictive tool has a high sensitivity and negative predictive value, hence the tool can be 
used a screening tool at triage to decide on admission of the patient. Patients with low scores 
on the prediction role (less than 8) are at low risk of IMS and can be managed in the ward and 
patients with higher scores (8 or more) and have a 50% risk of developing IMS and require 
intensive monitoring in an ICU setting. This tool requires validation in a prospective study. 
In our study, we also found that type of compound and WHO class of compound did not 
achieve statistical significance and the predictive tool does not utilise the entire range of the 
other risk factors as well. Hence if the risk factors (type and WHO class of compound) were 
removed from the scoring system and  neck muscle weakness (MRC grade 1-5), Namba scale 
(Latent, mild, moderate, severe) and Glasgow coma scale(GCS 3-15) were represented as a 
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continuous variable, the test might yield better results. This provides an area for further work 
to develop a reliable clinical prediction rule. 
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Limitations 
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LIMITATIONS OF THE STUDY 
 
Our study which looks at temporal relationship between peripheral muscular weakness and 
central encephalopathic manifestations was planned on 169 patients. But the final sample size 
was restricted to 78 patients due to time constraints. Hence the risk factor assessment maybe 
limited due to the smaller sample size. 
The assessment of neuromuscular weakness and sensorium done among patients who were 
mechanical ventilation were done after stopping sedation for a minimum of 4 to 6 hours. 
Hence the assessment may have overestimated patients with encephalopathy. 
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SUGGESTIONS AND FUTURE DIRECTIONS 
 
1) The predictive scoring system formed in this study can be further validated in a 
prospective study. 
2) The predictive score formed in this study can be further refined if the components 
such as Namba scale, neck muscle weakness (MRC grade) and Glasgow coma scale 
are used as a continuous variable. 
3) Further studies are required to understand the role of acetylcholinesterase inhibition, 
oxidative stress, altered mitochondrial bioenergetics and cytoprotection in 
encephalopathy in acute organophosphate poisoning 
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Conclusion 
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CONCLUSION 
1) The Incidence of Intermediate syndrome observed in this study is 33.3%. 
2) The risk factors for the development of intermediate syndrome identified in this study 
were: neck muscle weakness at admission (OR -7.87;CI – 1.86 - 33.4), sensorium 
assessed by Glasgow coma scale (OR - 1.38;CI – 0.36 -5.43) and severity of 
poisoning assessed by Namba scale(OR – 1.78;CI -  0.3 - 12.8). We have also 
observed that the type of compound, WHO class do not influence the occurrence of 
intermediate syndrome.  The observations seen in our study suggests that the most 
important determinant of intermediate syndrome is the poison load, 
acetylcholinesterase inhibition and the resulting severity of poisoning. 
 
3) Based on the risk factor analysis we propose a scoring system to predict the 
occurrence of Intermediate syndrome with sensorium assessed  by Glasgow coma 
scale (maximum score – 2), Severity of poisoning assessed by Namba scale(maximum 
score – 3), type of compound(maximum score – 2), WHO class of 
compound(maximum score – 2) and  neck muscle weakness(maximum score – 4). A 
score of < 8 is associated with a low risk of development of intermediate syndrome 
(area under the curve of 0.784 and sensitivity and specificity of 79% and 72% 
respectively). The positive predictive value negative predictive values were 56% and 
92% respectively. The prediction score can be used to screen patients in accident and 
emergency to triage patients who can be shifted to the ward and discharged earlier and 
those who require intensive care.  
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4) Three patterns of muscle paralysis were identified in this study. About half the 
patients did not develop any muscle paralysis. 20.5% developed early paralysis (Type 
I paralysis); 33.3% developed early paralysis that persisted beyond 72 hours (Type I 
and Type II paralysis continuum); 4 (5.1%) patients developed new onset weakness 
after 72 hours (pure Type II paralysis). The only distinguishing features between Type 
I and Type II paralysis were the severity of weakness and the duration of weakness 
which were greater in Type II paralysis. These results support the concept of a Type I 
Type II paralysis continuum. 
 
5) Early encephalopathy was seen in 23 patients (29.5%) and delayed encephalopathy, 
that is low sensorium developing after 72 hours after consumption or persisting low 
sensorium beyond 72 hours, was seen in 4 patients (5%). Patients who had developed 
delayed encephalopathy had low sensorium at admission, hence we have observed the 
early and delayed encephalopathy to be a spectrum disorder. 
 
 
6) Three patterns of the relationship between encephalopathy and muscle weakness were 
observed in our study. In the early phase of severe poisoning, most patients have 
encephalopathy and muscle weakness. In the first pattern, encephalopathy and muscle 
weakness both recover in 72 hours (13%). In the second pattern, encephalopathy 
recovers but the muscle weakness persists (13% of patients). In third pattern which 
occurred in 4(5%) patients encephalopathy and muscle weakness persist for > 72 
hours and recover together. The results suggest that encephalopathy and muscle 
weakness are closely inter-related phenomena both in early paralysis (Type I 
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paralysis) and delayed paralysis (Type II paralysis/intermediate syndrome). Based on 
the results we suggest that the delayed encephalopathy be referred to as intermediate-
encephalopathy syndrome rather than Delayed organophosphate encephalopathy 
(DOPE). Although patients with persistent encephalopathy require prolonged 
ventilation, the neurological recovery and prognosis is good.  
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Annexure I -  PROFORMA FOR THESIS:   Serial number: 
GENERAL INFORMATION 
1. Patient name: 
 
2. Patient ID: 
 
3. Age: 
 
4. Sex:          1.Male / 2.Female 
 
5. Marital status:         1.married / 2. Single / 3. Others 
 
6. Education:        1.Uneducated / 2.Educated   
 
7. Profession: 1.Unskilled/2.Semi-skilled/3.Skilled  
 
COMPOUND 
 
8. Compound identified:  Yes / no 
 
9. Compound  name:  
 
10. Method by which compound identified: Name given by patient/leaflet/bottle brought 
 
11. Type of compound : 1. Dimethyl  /  2. Diethyl  / 3. Others 
 
12. Percentage of compound : 
 
13. Compound quantity(volume):  
 
DETAIL REGARDING INGESTION 
 
14. Time and date of consumption:                                     
 
15. Time and date of First medical contact: 
 
16. Time and date of arrival ay CMC: 
 
17. Treatment given outside  :  1. Skin decontamination  /  2.Induced Emesis  /  3.  Gastric Lavage/ 
 
 4. Atropine  /  5. PAM  / 6.Intubation 
 
18. Toxidrome:  1. Salivation / 2. Lacrimation / 3. Urination / 4. Defaecation / 5. Vomiting / 6.Seizures /  
 
7. Breathlessness / 8. Fasciculations / 9.Altered sensorium 
 
19. Severity of poisoning by Namba scale:  Mild/Moderate/Severe 
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CLINICAL FEATURE – ON ADMISSION IN E&D 
 
20. GCS at presentatation: 
 
21. Pupils size:            PINPOINT / DILATED/ NORMAL (2-5MM) 
 
22. Pulse rate at presentation: 
 
23. Blood pressure at presentation: 
 
24. Respiratory rate at presentation: 
 
25. Saturation at presentation: 
 
26. Neck muscle weakness:   Present     /    Absent 
 
27. Fasciculation :  Present    /     Absent 
 
28. Limb muscle weakness: Upper limb and lower limb 
 
 
 
 DATE           
29)GCS           
30)Heart rate           
31)Blood pressure           
32)Toxidrome           
33)Ptosis(1.Yes/2.no 
/3.others 
 
          
34)Facial muscle 
weakness(1.Yes/2.No 
/3.Others) 
          
35)Extra-ocular 
movements(1.Present 
/2.Absent) 
          
36)Power-Shoulder           
37)Power-Elbow           
38)Power-Hip           
39)Power-knee           
40)Power-Neck(Neck 
muscle weakness) 
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41)Tone-Upper limb           
42)Tone-Lower limb 
 
          
43)Single breath 
count/FVC/Paradoxical 
respiration 
.          
44)Reflex-Biceps           
45)Reflex-Knee 
 
          
49)Reflex-Plantar .          
50)Fever(Fahrenheit)           
51)Time since last 
sedation: 
          
52)Atropine dose per 
day: 
          
           
 
 
53. Total duration of admission: 
 
54. Total duration of mechanical ventilation(if applicable): 
 
55. Outcome of patient: 1)Discharged and alive 2)discharged at request 3)Death 
 
56. Comments: 
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SUMMARY 
 
1. SERIAL NO 
 
2. COMPOUND 
 
3. TIME INTERVAL BETWEEN INGESTION AND FHC: 
 
 
4. PARALYSIS:  Type I paralysis/Type I-Type II paralysis (IMS) continuum/Type II 
paralysis alone (IMS) 
 
5. DURATION OF PARALYSIS:        Day     ___      to      Day  ___. 
  
6. MOST SEVERE PARALYSIS:  Muscle weakness grade in upper  ___    /   lower limb   
___. 
 
7. LOWEST SCORE OF GCS:          Day  ___        to       Day  ___. 
 
8. LOWEST SCORE OF GCS: 
 
9. INTERMEDIATE SYNDROME – PRESENT / ABSENT 
 
10. CENTRAL NERVOUS SYSTEM INVOLVEMENT – PRESENT / ABSENT 
 
 
11. PREDICITIVE SCORE 
 
 a) Neck muscle weakness    4  /  0                               d)Type      2 /  1 
 
b) Namba scale                    3 / 2 / 1 / 0                       e)Class      2 /  1 
 
c) GCS                                 2 / 1                                  TOTAL   -    
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ANNEXURE II - PATIENT INFORMATION SHEET : 
Scoring system to predict the development of Intermediate syndrome in patients with acute   
                                                     organophosphorus poisoning. 
                              
This study is to learn more about organophosphorus poisoning and its complications like 
weakness of muscles  and altered sensorium following poisoning. Organophosphorus 
poisoning is very common problem we face in our region but still we still do not have 
complete details about its common complications and how to recognize patients who may 
develop these complications. By undergoing this study you are helping us to understand  
organophosphorus poisoning. This may help future patients by improving the treatment 
offered to them. 
Participating in the study is entirely voluntary and you can decide to withdraw from the study 
at any point in time. This will not affect the treatment you will be undergoing in this hospital.   
Participating in the study includes signing a consent form and some additional tests:  
Electromyography(to assess your muscle function using a standard EMG machine which is 
safe and is being used regularly in our hospital). 
The subject will be examined daily by routine clinical methods as done by your treating 
doctor. This will not cause any added discomfort to the patient. 
As you can understand none of these tests involves any threat to life of the participant and 
will be mostly painless.  
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The information obtained in this study will be maintained confidential and the records will be 
accessed only the study investigators.    
If at any point if you have any clarification you can contact me 
(Contact Address: 
Dr. Nirmal Raj Francis 
Phone number : 09994393385 
Department of General Medicine Unit – 1 
Christian Medical College,  Vellore 
Tamil Nadu-632009) 
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                              ANNEXURE III – PATIENT CONSENT FORM 
Scoring system to predict the development of Intermediate syndrome in patients with acute  
                                                     organophosphorus poisoning. 
                                                    PATIENT CONSENT FORM 
 
Study Title: Temporal profile of central and peripheral neuromuscular features of acute Op 
poisoning. 
Subject’s Initials: _________ Subject’s Name: ________ 
Date of Birth / Age:_______ 
Please initial box  
(Subject) 
(i) I confirm that I have read and understood the information sheet dated _________ for the 
above study and have had the opportunity to ask questions. [ ] 
(ii) I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time, without giving any reason, without my medical care or legal 
rights being affected. [ ] 
 (iii) I understand that the Sponsor of the clinical trial, others working on the Sponsor’s 
behalf, the Ethics Committee and the regulatory authorities will not need my permission to 
look at my health records both in respect of the current study and any further research that 
may be conducted in relation to it, even if I withdraw from the trial. I agree to this access. 
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However, I understand that my identity will not be revealed in any information released to 
third parties or published. [ ] 
(iv) I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s) [ ] 
(v) I agree to take part in the above study. [ ] 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable 
Representative:_____________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
 
Signature of the Witness: ___________________________ 
Date:_____/_____/_______ 
Name of the Witness: ______________________________ 
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